The Pill That Could Replace Your Kid's Daily Shot

The drug actually has an interesting backstory. It started life as a Novartis cancer compound. In 2016, researchers showed it could counteract the biology of achondroplasia in preclinical studies. BridgeBio licensed the rights from Novartis in January 2018 and created a subsidiary called QED Therapeutics to develop it. The first child in a clinical trial was dosed in July 2020.

Infigratinib even earned an FDA accelerated approval in May 2021, but for a completely different disease: a rare bile duct cancer called cholangiocarcinoma. The achondroplasia program was always the longer play, requiring years of pediatric trials to prove it worked safely in kids.

The Data That Got the FDA's Attention

BridgeBio's pivotal study was called PROPEL 3: a global, randomized, double-blind, placebo-controlled Phase 3 trial in children ages 3 to 17 with open growth plates. The gold standard of clinical trial design.

The primary endpoint was change in annualized height velocity (how fast kids grow per year) at 52 weeks. And the results were convincing. Kids on infigratinib grew 1.74 cm/year faster than those on placebo by the statistical measure, with an observed difference of 2.10 cm/year. The drug also hit its key secondary endpoint on height Z-score, which measures a child's height relative to peers.

To put that in context: an extra 2 centimeters per year might sound small, but compounded over a childhood of treatment, it could meaningfully change outcomes. These results were published in the New England Journal of Medicine, which tells you the scientific community took them seriously.

Earlier Phase 2 data from the PROPEL 2 study had already shown a similar signal, with a +2.51 cm/year improvement at 12 months in one cohort.

Why "Oral" Is the Magic Word

In rare pediatric diseases, how you deliver a drug matters almost as much as whether it works. Parents of kids with achondroplasia aren't just evaluating efficacy charts; they're thinking about school mornings, sleepovers, summer camp, and the daily negotiation of convincing a child to accept a needle.

An oral therapy eliminates all of that friction. No special storage, no injection training, no tearful standoffs before breakfast. The oral profile isn't just a clinical differentiator; it's a commercial weapon.

BridgeBio says it's prepared to launch if the FDA gives a green light. The company also plans to file with European regulators (the EMA) by the end of 2026, signaling global ambitions.

BioMarin Should Be Paying Attention

Vosoritide generated significant revenue for BioMarin, and the drug isn't going away overnight. It has a head start, real-world data, and physician familiarity on its side. But the competitive moat just got a lot shallower.

Consider the pitch to a pediatric endocrinologist: "Here's a pill that works through a different mechanism, showed strong growth data in a rigorous Phase 3, and doesn't require your patient to get a daily injection." That's a compelling story, especially for families who've struggled with adherence or who are newly diagnosed and choosing a first therapy.

The achondroplasia market is becoming a three-or-four-player race, and BridgeBio just moved to the inside lane.

What Happens Next

The clock is ticking toward February 4, 2027. Priority Review means the FDA considers this application important enough to fast-track its evaluation (six months instead of the standard ten). Between now and then, expect an advisory committee meeting, more analyst notes, and plenty of speculation about launch strategy and pricing.

For the families at the center of all this, though, the calculus is simpler. A pill versus a needle. Every parent knows which one they'd choose.

The Drug That Could Rewrite How We Treat the Most Common Blood Cancer

AbbVie and Genmab's epcoritamab just delivered a 51% reduction in disease progression when added to frontline chemo for the most common aggressive lymphoma. After 30 years of the same standard of care, the first-line DLBCL playbook may finally be getting a rewrite.